Clinical Trial Update: TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers [NA]

View source ↗

Summary

Clinical trial evaluating TraceIT Tissue Marker to identify primary resection bed margins in oropharyngeal cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Cancer

Drugs mentioned

• TraceIT Tissue Marker (TraceIT Tissue Marker)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Oropharyngeal Cancer | NA | Status: TERMINATED | Results posted: 2022-07-12